Pictet Asset Management (Switzerland)’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-481,827	Closed	-$930K	–	1627
2022 Q2	$930K	Buy	481,827 +55,556	+13%	+$121K	﹤0.01%	1054
2022 Q1	$1.27M	Buy	426,271 +91,227	+27%	+$343K	﹤0.01%	1027
2021 Q4	$1.5M	Buy	335,044 +157,153	+88%	+$746K	﹤0.01%	1027
2021 Q3	$865K	Buy	+177,891	New	+$980K	﹤0.01%	1098

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s PRTK Position: Q3 2022 in Review

Pictet Asset Management (Switzerland) sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 481,827 shares — an estimated $930K sold.

Pictet Asset Management (Switzerland) first reported a position in PRTK in Q3 2021 and held it in 4 quarters. The position peaked at $1.5M in Q4 2021. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

Pictet Asset Management (Switzerland) reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Pictet Asset Management (Switzerland) sold 481,827 Paratek Pharmaceuticals, Inc. shares in Q3 2022, an estimated $930K.
Pictet Asset Management (Switzerland) first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2021 and held it in 4 quarters.
Pictet Asset Management (Switzerland)'s Paratek Pharmaceuticals, Inc. position peaked at $1.5M in Q4 2021.
72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q3 2022, filed 14 Nov 2022.